Evaluating the role of Tregs in the progression of multiple myeloma
- PMID: 30773086
- DOI: 10.1080/10428194.2019.1579324
Evaluating the role of Tregs in the progression of multiple myeloma
Abstract
The role of regulatory T-cells (Treg) and Th17 cells in the progression of multiple myeloma has been unclear. There are conflicting reports of the Treg and Th17 frequency being increased, decreased, and unchanged as compared with controls. In this study, we sought to characterize the T-cell subsets including Treg function in both blood and marrow compartments of monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM). The Treg/Th17 ratio is skewed toward the suppressive phenotype in MGUS and MM. There are more activated and memory Tregs in the myeloma marrow. Although the myeloma Tregs are functional, they are less suppressive than Tregs in chronic lymphocytic leukemia where they drive disease progression. None of the T-cell subsets were found to have a clinical correlation with time to progression in MGUS or progression-free survival in myeloma. Tregs are important but unlikely major players in the progression of MGUS to MM.
Keywords: T-cell subsets; monoclonal gammopathy of undetermined significance; multiple myeloma.
Similar articles
-
Mass Cytometry Discovers Two Discrete Subsets of CD39-Treg Which Discriminate MGUS From Multiple Myeloma.Front Immunol. 2019 Aug 2;10:1596. doi: 10.3389/fimmu.2019.01596. eCollection 2019. Front Immunol. 2019. PMID: 31428081 Free PMC article.
-
Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role.J Immunol Res. 2016;2016:9271469. doi: 10.1155/2016/9271469. Epub 2016 Jul 14. J Immunol Res. 2016. PMID: 27493974 Free PMC article.
-
Circulating Regulatory T-Cell Number Does Not Predict Prognosis of Monoclonal Gammopathies of Uncertain Significance.Crit Rev Eukaryot Gene Expr. 2021;31(5):21-26. doi: 10.1615/CritRevEukaryotGeneExpr.2021038544. Crit Rev Eukaryot Gene Expr. 2021. PMID: 34591386
-
Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma.Front Immunol. 2021 Feb 23;12:620596. doi: 10.3389/fimmu.2021.620596. eCollection 2021. Front Immunol. 2021. PMID: 33708212 Free PMC article. Review.
-
Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.Int J Mol Sci. 2019 Jun 10;20(11):2822. doi: 10.3390/ijms20112822. Int J Mol Sci. 2019. PMID: 31185596 Free PMC article. Review.
Cited by
-
Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma.Cancers (Basel). 2020 Nov 4;12(11):3245. doi: 10.3390/cancers12113245. Cancers (Basel). 2020. PMID: 33158030 Free PMC article.
-
Different expression patterns of VISTA concurrent with PD-1, Tim-3, and TIGIT on T cell subsets in peripheral blood and bone marrow from patients with multiple myeloma.Front Oncol. 2022 Nov 10;12:1014904. doi: 10.3389/fonc.2022.1014904. eCollection 2022. Front Oncol. 2022. PMID: 36439426 Free PMC article.
-
Treating Multiple Myeloma in the Context of the Bone Marrow Microenvironment.Curr Oncol. 2022 Nov 21;29(11):8975-9005. doi: 10.3390/curroncol29110705. Curr Oncol. 2022. PMID: 36421358 Free PMC article. Review.
-
What happens to regulatory T cells in multiple myeloma.Cell Death Discov. 2023 Dec 21;9(1):468. doi: 10.1038/s41420-023-01765-8. Cell Death Discov. 2023. PMID: 38129374 Free PMC article. Review.
-
Harnessing the Potential of NK Cell-Based Immunotherapies against Multiple Myeloma.Cells. 2022 Jan 24;11(3):392. doi: 10.3390/cells11030392. Cells. 2022. PMID: 35159200 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical